1.26  0 (0%)		10-07 14:00
Open: 1.23 High: 1.29 Volume: 73,802		Pre. Close: 1.26 Low: 1.21 Market Cap: 25(M)

Short term
Mid term
Targets	6-month :	1.69	1-year :	1.98
Resists	First :	1.45	Second :	1.69
Pivot price	1.27
Supports	First :	1.1	Second :	0.88
MAs	MA(5) :	1.23	MA(20) :	1.27
	MA(100) :	1	MA(250) :	1.06
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	63.9	D(3) :	60.1
RSI	RSI(14): 60.8
52-week	High :	2.32	Low :	0.4

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NRSN ] has closed above bottom band by 43.8%. Bollinger Bands are 50% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.28 - 1.29	1.29 - 1.29
Low:	1.21 - 1.21	1.21 - 1.22
Close:	1.25 - 1.26	1.26 - 1.27

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Mon, 07 Oct 2024
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting - PR Newswire

Mon, 30 Sep 2024
NeuroSense Therapeutics Reports Mid-Year Financials - TipRanks

Tue, 24 Sep 2024
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's - StockTitan

Tue, 24 Sep 2024
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PR Newswire

Tue, 24 Sep 2024
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - StockTitan

Fri, 30 Aug 2024
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	19 (M)
Shares Float	13 (M)
Held by Insiders	25.4 (%)
Held by Institutions	8.5 (%)
Shares Short	386 (K)
Shares Short P.Month	140 (K)

EPS	-0.65
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.1
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-150.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.61
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-1.94
PEG Ratio	0
Price to Book value	-14
Price to Sales	0
Price to Cash Flow	-2.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.